ACHIEVE LIFE SCIENCES, INC.
ACHVDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
Custirsen
Prostate Cancer
cabazitaxel
Prostate Cancer
Cytisinicline
Smoking Cessation
custirsen sodium
Non-small Cell Lung Cancer
OGX-427 600 mg
Urologic Neoplasms
TOCOSOL Paclitaxel
Bladder Neoplasms
TOCOSOL(R) Paclitaxel
Breast Cancer
S-8184 Paclitaxel Injectable Emulsion
Urologic Neoplasms
custirsen (OGX-011)/mitoxantrone
Prostate Cancer
Cytisine
Smoking Cessation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Custirsen | Phase 3 | Prostate Cancer | - | - |
cabazitaxel | Phase 3 | Prostate Cancer | - | - |
Cytisinicline | Phase 3 | Smoking Cessation | - | - |
custirsen sodium | Phase 3 | Non-small Cell Lung Cancer | - | - |
OGX-427 600 mg | Phase 2 | Urologic Neoplasms | - | - |
TOCOSOL Paclitaxel | Phase 2 | Bladder Neoplasms | - | - |
TOCOSOL(R) Paclitaxel | Phase 2 | Breast Cancer | - | - |
S-8184 Paclitaxel Injectable Emulsion | Phase 2 | Urologic Neoplasms | - | - |
custirsen (OGX-011)/mitoxantrone | Phase 2 | Prostate Cancer | - | - |
Cytisine | Phase 2 | Smoking Cessation | - | - |